4.2 Article

Dabigatran anticoagulation and Stanford type A aortic dissection: lethal coincidence

Journal

ACTA ANAESTHESIOLOGICA SCANDINAVICA
Volume 58, Issue 5, Pages 630-637

Publisher

WILEY
DOI: 10.1111/aas.12303

Keywords

-

Categories

Funding

  1. Swiss National Science Foundation, Berne, Switzerland [33CM30_124117, 406440-131268]
  2. Swiss Society of Anesthesiology and Reanimation (SGAR), Berne, Switzerland
  3. Swiss Foundation for Anesthesia Research, Zurich, Switzerland
  4. Bundesprogramm Chancengleichheit, Berne, Switzerland
  5. CSL Behring, Berne, Switzerland
  6. Vifor SA, Villars-sur-Gl ne, Switzerland
  7. Novo Nordisk A/S, Bagsvard, Denmark
  8. Swiss National Science Foundation (SNF) [33CM30-124117] Funding Source: Swiss National Science Foundation (SNF)

Ask authors/readers for more resources

BackgroundNovel oral anticoagulants are now encountered in patients needing emergency surgery. Knowledge and treatment options are limited. Methods and resultWe present the case of a 76-year-old patient who suffered from an acute Stanford type A aortic dissection, needing emergency surgical aortic repair. He was anticoagulated with dabigatran due to past atrial fibrillation. Despite haemodiafiltration, surgical revision and massive transfusion of packed red blood cells, fresh frozen plasma, platelets, coagulation factors, and recombinant factor VIIa, the patient died from intractable bleeding with sustained therapeutic levels of dabigatran. ConclusionAfter reviewing the literature, we summarize the limited treatment options and show possible approaches for patients treated with dabigatran needing emergency surgery.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available